RAPT Therapeutics is a clinical-stage biopharmaceutical company that develops and commercializes small molecule therapies for patients with unmet needs in inflammatory diseases and oncology. Its drug candidate RPT193 selectively inhibits the migration of type 2 T helper cells into inflamed tissues. FLX475, an oral small molecule CCR4 antagonist, is in the Phase 1/2 clinical trial to investigate its potential as a monotherapy or in combination with pembrolizumab in patients with advanced cancer.